Work

Abstract 4958: VTP50469 is a novel, orally available menin-MLL1 inhibitor effective against MLL-rearranged and NPM1-mutant leukemia

Year: 2018

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2018-4958

Authors: Andrei V. Krivtsov, Benjamin K. Eschle, Matthew Witkin, Jayant Y. Gadrey, Hannah J. Uckelmann, Sayuri Kitajima, Gerard M. McGeehan, Scott A. Armstrong

Institutions: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Syndax Pharmaceuticals (United States)

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2885586780

Cites:

Cited by: 1

Related to: 10